Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center Kristina D. Woodhouse, MD, Wei-Ting.

Slides:

Advertisements

Similar presentations

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

Advertisements

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial K. Ranh Voong, MD MPH, Lincy S. Lal, PhD, Deborah.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes Stuart E. Samuels, MD, PhD, Matthew.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Prevalence and Distribution of Sub-Clinical Atherosclerosis by Screening Vascular Ultrasound in Low and Intermediate Risk Adults: The New York Physicians.

Clinical application of lying-on-the-floor total skin electron irradiation for frail patients with cutaneous lymphoma: An emphasis on the importance of.

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards Charles S. Mayo, PhD, John.

Ajay Chaudry, PhD, Christopher Wimer, PhD Academic Pediatrics

Copyright © 2012 American Medical Association. All rights reserved.

Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.

Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial Daniel A. Hamstra, MD, PhD, Neil Mariados,

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy Fady F. Youssef, MS, Parag.

Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy Dawn Owen, MD, PhD, Charles S. Mayo, PhD,

Risk of carotid blowout after reirradiation with particle therapy

Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging Y. Jessica Huang, PhD,

Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam– Generated Neutrons Leo E. Gerweck, PhD, Peigen Huang, MD, Hsiao-Ming.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

Effect of variations in atelectasis on tumor displacement during radiation therapy for locally advanced lung cancer Nathan Tennyson, MD, Elisabeth Weiss,

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy William.

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.

Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Cryptic Nocardia nova brain abscess postradiation treatment and neurosurgery in a patient with small cell lung cancer: A case report and review of the.

Catherine W. Gillespie, PhD, MPH, Pamela E. Morin, MBA

Aaron S. Kusano, MD, SM, Matthew J

Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity.

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs Joseph F. Fowler, MD, Arindam Ghosh,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Age at menarche: a predictor of diminished ovarian function?

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Reduction of C-reactive protein levels through use of a multivitamin

Brenda G. Clark, PhD, Robert J

Safety of differential radiation dosing in lymph node positive necks treated with IMRT Stephen Sozio, MBS, Zorimar Rivera-Núñez, PhD, Omar Mahmoud, MD,

Sabina Hunziker, MD, MPH, Jennifer Stevens, MD, MS, Michael D

Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006 Mark.

Dosimetric comparison of 3-dimensional conformal radiation therapy and intensity modulated radiation therapy and impact of setup errors in lower limb.

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality.

Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain David S. Guzick, M.D.,

Ajay Chaudry, PhD, Christopher Wimer, PhD Academic Pediatrics

Volume 17, Issue 7, Pages S70-S78 (September 2017)

American Society for Radiation Oncology's Performance Assessment for the Advancement of Radiation Oncology Treatment: A practical approach for informing.

Timeliness Across the Continuum of Care in Veterans with Lung Cancer

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Alex K. Bryant, BS, Robert C. Mundt, HSDG, Ajay P. Sandhu, MD, James J

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

An Editorial Note: The Long Arm of Practical Radiation Oncology

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Sean Ackerman, M. D. , Julia Wenegrat, M. A. , David Rettew, M. D

Ann G. Schwartz, PhD, Michele L. Cote, PhD, Angela S

Safety considerations for IMRT: Executive summary

Using Your Personal Mission Statement to INSPIRE and Achieve Success

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis William A. Stokes, MD, Brian.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prevalence and Risk Factors for Erectile Dysfunction in the US

What is quality in a transplant program?

Primer of statistics in dental research: Part I

Peter A. McCullough, MD, MPH, Christopher T. Chan, MD, Eric D

George L. Bakris, MD, John M. Burkart, MD, Eric D

Changing practice patterns for breast cancer radiation therapy with clinical pathways: An analysis of hypofractionation in a large, integrated cancer.

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018 Thomas M. Pisansky, MD, Ian M. Thompson,

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center Kristina D. Woodhouse, MD, Wei-Ting Hwang, PhD, Neha Vapiwala, MD, Akansha Jain, Xingmei Wang, MS, Stefan Both, PhD, Meera Shah, BS, Marquise Frazier, RT(T), MBA, Peter Gabriel, MD, John P. Christodouleas, MD, MPH, Zelig Tochner, MD, Curtiland Deville, MD Advances in Radiation Oncology Volume 2, Issue 2, Pages 132-139 (April 2017) DOI: 10.1016/j.adro.2017.01.004 Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 1 Univariable and multivariable analysis of proton therapy use for low- and intermediate-risk prostate cancer by race, age, distance, and poverty. Advances in Radiation Oncology 2017 2, 132-139DOI: (10.1016/j.adro.2017.01.004) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 2 Percentage use of proton therapy versus intensity modulated radiation therapy per treatment year (2010-2015) for low- and intermediate risk prostate cancer. *Significant difference and error bars represent the 95% confidence interval. Advances in Radiation Oncology 2017 2, 132-139DOI: (10.1016/j.adro.2017.01.004) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions